[1]张 欣,熊 斌,姚 琦,等.巨大肝海绵状血管瘤经导管动脉硬化栓塞治疗的有效性和安全性分析[J].介入放射学杂志,2015,(11):992-995.
 ZHANG Xin,XIONG Bin,YAO Qi,et al.Transcatheter arterial sclerotic embolization for the treatment of giant hepatic cavernous hemangioma: analysis of the effectiveness and the safety[J].journal interventional radiology,2015,(11):992-995.
点击复制

巨大肝海绵状血管瘤经导管动脉硬化栓塞治疗的有效性和安全性分析 ()

PDF下载中关闭

分享到:

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
期数:
2015年11期
页码:
992-995
栏目:
临床研究
出版日期:
2015-11-25

文章信息/Info

Title:
Transcatheter arterial sclerotic embolization for the treatment of giant hepatic cavernous hemangioma: analysis of the effectiveness and the safety
作者:
张 欣 熊 斌 姚 琦 郑传胜
Author(s):
ZHANG Xin XIONG Bin YAO Qi ZHENG Chuan- sheng
Department of Interventional Radiology, Affiliated Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province 430022, China
关键词:
【关键词】 肝海绵状血管瘤 经导管动脉硬化栓塞 平阳霉素碘油混合乳剂 明胶海绵颗粒
文献标志码:
A
摘要:
【摘要】 目的 探讨经导管动脉硬化栓塞术(TASE)治疗巨大肝海绵状血管瘤(CHL)的有效性和安全性。方法 对22例巨大CHL患者采用平阳霉素碘油混合乳剂(PLE)行TASE治疗。所有患者TASE术后随访3~6个月,复查临床症状、瘤体变化及是否出现严重并发症。结果 TASE术成功率100%,13例术前有临床症状患者术后均缓解或消失。术后随访3~6个月复查血管瘤体,由术前平均最大直径(14.4±4.7) cm缩小为术后平均最大直径(9.5±4.1) cm,差异有统计学意义(P<0.05)。未出现肝脓肿、胆管狭窄、胆管坏死等严重并发症。部分患者行多次TASE治疗。结论 TASE术治疗巨大CHL创伤小、安全可靠、并发症少,值得广泛应用于临床治疗。

参考文献/References:

[1] 欧阳墉, 张学军, 欧阳雪晖, 等. 肝海绵状血管瘤的研究进展——图例式阐述[J]. 介入放射学杂志, 2012, 21: 1- 6.
[2] Biecker E, Fischer HP, Strunk H, et al. Benign hepatic tumours[J]. Z Gastroenterol, 2003, 41: 191- 200.
[3] Corigliano N, Mercantini P, Amodio PM, et al. Hemoperitoneum from a spontaneous rupture of a giant hemangioma of the liver: report of a case[J]. Surg Today, 2003, 33: 459- 463.
[4] Trotter JF, Everson GT. Benign focal lesions of the liver[J]. Clin Liver Dis, 2001, 5: 17- 42.
[5] Choi BY, Nguyen MH. The diagnosis and management of benign hepatic tumors[J]. J Clin Gastroenterol, 2005, 39: 401- 412.
[6] Trastek VF, van Heerden JA, Sheedy PF 2nd, et al. Cavernous hemangiomas of the liver: resect or observe?[J]. Am J Surg, 1983, 145: 49- 53.
[7] Herman P, Costa ML, Machado MA, et al. Management of hepatic hemangiomas: a 14- year experience[J]. J Gastrointest Surg, 2005, 9: 853- 859.
[8] Erdogan D, Busch OR, Van Delden OM, et al. Management of liver hemangiomas according to size and symptoms[J]. J Gast- roenterol Hepatol, 2007, 22: 1953- 1958.
[9] 肖晋昌, 祖茂衡, 徐 浩, 等. 平阳霉素瘤体内注射治疗肝血管瘤60例临床分析[J]. 介入放射学杂志, 2013, 22: 334- 336.
[10] Srivastava DN, Gandhi D, Seith A, et al. Transcatheter arterial embolization in the treatment of symptomatic cavernous hemangiomas of the liver: a prospective study[J]. Abdom Imaging, 2001, 26: 510- 514.
[11] Deutsch GS, Yeh KA, Bates WB, et al. Embolization for management of hepatic hemangiomas[J]. Am Surg, 2001, 67: 159- 164.
[12] Granov AM, Tarazov PG, Polysalov VN. Arterial embolization in treatment of hepatic cavernous hemangioma[J]. Khirurgiia (Mosk), 1999, 4: 13- 17.
[13] Giavroglou C, Economou H, Ioannidis I. Arterial embolization of giant hepatic hemangiomas[J]. Cardiovasc Intervent Radiol, 2003, 26: 92- 96.
[14] 蒋旭远, 徐 克. 平阳霉素碘油乳剂动脉栓塞治疗肝血管瘤的中远期疗效评价[J]. 介入放射学杂志, 2012, 21: 31- 34.
[15] 孔 鹏, 鹿化伟, 王家平, 等. 平阳霉素碘油乳剂超选择硬化性栓塞治疗肝血管瘤[J]. 介入放射学杂志, 2011, 20: 123- 126.
[16] 尹 君, 梁惠民, 冯敢生, 等. 肝血管瘤合并动静脉瘘的DSA表现及介入治疗[J]. 放射学实践, 2005, 20: 1010- 1013.
[17] 黄晓强, 黄志强, 段伟东, 等. 肝海绵状血管瘤肝动脉栓塞后的肝胆并发症及其处理(附9例报告)[J]. 中国实用外科杂志, 2001, 21: 319- 320.
[18] 刘 伟, 陈根生, 陈洪波, 等. 肝海绵状血管瘤的肝动脉栓塞治疗及并发症分析[J]. 介入放射学杂志, 2004, 13: 428- 430.

相似文献/References:

[1]胡清雯,陈 夷. 微波消融治疗肝海绵状血管瘤致并发症分析及其防治[J].介入放射学杂志,2014,(06):500.
 HU Qing- wen,CHEN Yi.. Microwave ablation for the treatment of hepatic cavernous hemangiomas: its serious complications and their prevention and treatment[J].journal interventional radiology,2014,(11):500.
[2]于长路,纪盛章,贾科峰,等. 不同栓塞剂治疗肝巨大海绵状血管瘤的疗效[J].介入放射学杂志,2014,(06):525.
 YU Chang- lu,JI Sheng- zhang,JIA Ke- feng,et al. Therapeutic effect of interventional embolization for giant hepatic cavernous hemangiomas: comparison of different embolic agents[J].journal interventional radiology,2014,(11):525.

备注/Memo

备注/Memo:
(收稿日期:2015-02-15)
(本文编辑:边 佶)
更新日期/Last Update: 2015-11-24